Inflammatory Mechanisms of Diabetes and Its Vascular Complications

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 May 28

PMID 35625904

Authors

Lyudmila V Nedosugova

Yuliya V Markina

Leyla A Bochkareva

Irina A Kuzina

Nina A Petunina

Irina Y Yudina

Tatiana V Kirichenko

Affiliations

Soon will be listed here.

Abstract

The main cause of death in patients with type 2 DM is cardiovascular complications resulting from the progression of atherosclerosis. The pathophysiology of the association between diabetes and its vascular complications is complex and multifactorial and closely related to the toxic effects of hyperglycemia that causes increased generation of reactive oxygen species and promotes the secretion of pro-inflammatory cytokines. Subsequent oxidative stress and inflammation are major factors of the progression of type 2 DM and its vascular complications. Data on the pathogenesis of the development of type 2 DM and associated cardiovascular diseases, in particular atherosclerosis, open up broad prospects for the further development of new diagnostic and therapeutic approaches.

Citing Articles

Circulating mannose-binding lectin in diabetic patients and risk of vascular complications: a systematic review and meta-analysis.

Sedghi M, Ranjbaran A, Forouhi M, Nejatianfar M, Azmi-Naei N, Esfahani P J Diabetes Metab Disord. 2024; 23(2):2131-2142.

PMID: 39610514 PMC: 11599526. DOI: 10.1007/s40200-024-01478-4.

Metabolic reprogramming of macrophages in the context of type 2 diabetes.

Witcoski Junior L, de Lima J, Somensi A, de Souza Santos L, Paschoal G, Uada T Eur J Med Res. 2024; 29(1):497.

PMID: 39407333 PMC: 11481356. DOI: 10.1186/s40001-024-02069-y.

Editorial to the Special Issue "Molecular and Cellular Mechanisms of CVD: Focus on Atherosclerosis".

Nikiforov N Biomedicines. 2024; 12(9).

PMID: 39335661 PMC: 11430762. DOI: 10.3390/biomedicines12092148.

Presepsin Levels in Infection-Free Subjects with Diabetes Mellitus: An Exploratory Study.

Kouroupis D, Zografou I, Balaska A, Reklou A, Varouktsi A, Paschala A Biomedicines. 2024; 12(9).

PMID: 39335474 PMC: 11428571. DOI: 10.3390/biomedicines12091960.

Transcutaneous vagus nerve stimulation has no anti-inflammatory effect in diabetes.

Okdahl T, Kufaishi H, Kornum D, Bertoli D, Krogh K, Knop F Sci Rep. 2024; 14(1):21042.

PMID: 39251831 PMC: 11385211. DOI: 10.1038/s41598-024-72139-y.

References

Kytovuori L, Lipponen J, Rusanen H, Komulainen T, Martikainen M, Majamaa K . A novel mutation m.8561C>G in MT-ATP6/8 causing a mitochondrial syndrome with ataxia, peripheral neuropathy, diabetes mellitus, and hypergonadotropic hypogonadism. J Neurol. 2016; 263(11):2188-2195. DOI: 10.1007/s00415-016-8249-2. View

Luna P, Guarner V, Farias J, Hernandez-Pacheco G, Martinez M . Importance of Metabolic Memory in the Development of Vascular Complications in Diabetic Patients. J Cardiothorac Vasc Anesth. 2016; 30(5):1369-78. DOI: 10.1053/j.jvca.2016.02.008. View

Klimcakova E, Moro C, Mazzucotelli A, Lolmede K, Viguerie N, Galitzky J . Profiling of adipokines secreted from human subcutaneous adipose tissue in response to PPAR agonists. Biochem Biophys Res Commun. 2007; 358(3):897-902. DOI: 10.1016/j.bbrc.2007.05.012. View

Tanti J, Gremeaux T, Van Obberghen E, Le Marchand-Brustel Y . Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem. 1994; 269(8):6051-7. View

Lebovitz H . Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019; 19(12):151. PMC: 6881429. DOI: 10.1007/s11892-019-1270-y. View

Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati F, Powe N . Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004; 141(6):421-31. DOI: 10.7326/0003-4819-141-6-200409210-00007. View

Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T . Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab. 2011; 14(3):283-7. DOI: 10.1111/j.1463-1326.2011.01526.x. View

Derosa G, Maffioli P . α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012; 8(5):899-906. PMC: 3506243. DOI: 10.5114/aoms.2012.31621. View

Rovira-Llopis S, Banuls C, Diaz-Morales N, Hernandez-Mijares A, Rocha M, Victor V . Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. Redox Biol. 2017; 11:637-645. PMC: 5284490. DOI: 10.1016/j.redox.2017.01.013. View

10.

Hossain U, Das A, Ghosh S, Sil P . An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications. Food Chem Toxicol. 2020; 145:111738. PMC: 7480666. DOI: 10.1016/j.fct.2020.111738. View

11.

Bubb K, Drummond G, Figtree G . New opportunities for targeting redox dysregulation in cardiovascular disease. Cardiovasc Res. 2019; 116(3):532-544. DOI: 10.1093/cvr/cvz183. View

12.

Emoto T, Sawada T, Hashimoto M, Kageyama H, Terashita D, Mizoguchi T . Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2011; 109(1):42-6. DOI: 10.1016/j.amjcard.2011.08.005. View

13.

Stumvoll M, Goldstein B, van Haeften T . Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005; 365(9467):1333-46. DOI: 10.1016/S0140-6736(05)61032-X. View

14.

Brown E, Rajeev S, Cuthbertson D, Wilding J . A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019; 21 Suppl 2:9-18. DOI: 10.1111/dom.13650. View

15.

Nauck M, Meier J . MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur J Endocrinol. 2019; 181(6):R211-R234. DOI: 10.1530/EJE-19-0566. View

16.

Hotamisligil G, Peraldi P, Budavari A, Ellis R, White M, Spiegelman B . IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271(5249):665-8. DOI: 10.1126/science.271.5249.665. View

17.

Li M, Zhu Y, Jaiswal S, Liu N . Mitochondria Homeostasis and Vascular Medial Calcification. Calcif Tissue Int. 2021; 109(2):113-120. DOI: 10.1007/s00223-021-00828-1. View

18.

Lamichane S, Dahal Lamichane B, Kwon S . Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis. Int J Mol Sci. 2018; 19(4). PMC: 5979443. DOI: 10.3390/ijms19040949. View

19.

Thangavel N, Al Bratty M, Javed S, Ahsan W, Alhazmi H . Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs. Int J Med Chem. 2017; 2017:1069718. PMC: 5474549. DOI: 10.1155/2017/1069718. View

20.

Bassaganya-Riera J, Song R, Roberts P, Hontecillas R . PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol. 2010; 23(4):343-52. DOI: 10.1089/vim.2010.0016. View